Exelon Patch Articles

Actavis confirms generic Exelon Patch patent challenge; InnoPharma debuts generic Vistide in USA

9 March 2013

European Alzheimer's drug market to grow to $4.78 billion by 2019, says F&S

25 November 2012

FDA backs higher dose of Novartis Exelon Patch for Alzheimer's

4 September 2012

Novartis posts 50% 4th-qtr 2009 profits rise and promotes drugs chief Jimenez to CEO; other top changes

26 January 2010

Novartis' 1st-qtr 2009 results boosted by new products

24 April 2009

CHMP gives nod to Wyeth's Conbriza, Fresenius' Removab, Nycomed's Pantozol, etc

2 March 2009

EU researchers find potential new link between AD and amyloid plaques

2 June 2008

Vaccines and diagnostics help Swiss major Novartis beat expectations

28 April 2008

Novartis' Exelon not widely used by PCPs

3 December 2007

Despite strong nine-month results at Novartis, pharma heads will roll

29 October 2007

Novartis' Exelon patch launched in the UK

29 October 2007

Tokyo stocks to October 8, 2007

15 October 2007

Exelon gets EC OK for Alzheimer's disease

1 October 2007

CHMP recommends approval Exelon patch

30 July 2007

Japan stock market week to July 16, 2007

23 July 2007

Stock Commentary - Europe - week to July 9, 2007

16 July 2007

Novartis' Exelon Patch gets US FDA OK for Alzheimer's and Parkinson's diseases

16 July 2007

Novartis' Exelon patch "better than tablet"

31 July 2006

New paradigms in Alzheimer's disease therapy presented at ICAD 2006

31 July 2006

Showing 1-19 of 19 articles

Go to beginningPrevious
  • 1
NextGo to end